Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8433432 | 1.00 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4124283 | 0.98 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL27474184 | 0.96 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL28611075 | 0.96 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL1535851 | 0.91 | — | — | |
| SCHEMBL28413576 | 0.88 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8430106 | 0.86 | L3MBTL1 (0.53) | L3MBTL1MEN1KMT2ATDP1CES2 | |
| SCHEMBL5874880 | 0.86 | L3MBTL1 (0.47) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8431983 | 0.84 | L3MBTL1 (0.52) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8430031 | 0.84 | L3MBTL1 (0.52) | ALDH1A1L3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312267-A1 | Diagnosis and Treatment of Diseases Arising from Defects in the Tuberous Sclerosis Pathway | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-12-18 | — | — | US | claimed |
| CN-100374158-C | Diagnosis and treatment of the tuberous sclerosis pathway | UNIV MICHIGAN (US) | 2008-03-12 | — | — | CN | claimed |
| US-20250223297-A1 | NOVEL RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | disclosed |
| CN-118804981-A | Method for processing biomass material | 普罗奥尼克股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-12091424-B2 | Rapamycin derivatives | NOVARTIS AG (CH) | 2024-09-17 | — | — | US | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| US-20240180894-A1 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | BETTERLIFE PHARMA INC (CA) | 2024-06-06 | — | — | US | disclosed |
| EP-4365179-A2 | NOVEL RAPAMYCIN DERIVATIVES | Novartis AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| CN-114477249-B | Method for preparing high-purity magnesium hydroxide and calcium sulfate by adopting calcium carbide furnace purification ash | 龙岩紫云化学科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117417351-A | rapamycin derivatives | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| EP-3687999-B1 | RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-5212155-A | And cyclosporin, antibiotics | CALNE ROY (GB) | 1993-05-18 | — | — | US | disclosed |
| WO-1992017490-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS INHIBITORS OF RETROVIRUSES | THE UPJOHN COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
| CN-1016507-B | Process for preparation of forskolin derivatives | NIPPON KAYAKU KK (JP) | 1992-05-06 | — | — | CN | disclosed |
| US-5100899-A | METHODS OF INHIBITING TRANSPLANT REJECTION IN MAMMALS USING RAPAMYCIN AND DERIVATIVES AND PRODRUGS THEREOF | CALNE ROY (GB) | 1992-03-31 | — | — | US | disclosed |
| EP-0429436-A2 | Prodrugs of rapamycin | THE UNIVERSITY OF KANSAS (US) | 1991-05-29 | — | — | EP | disclosed |
| EP-0401747-A2 | Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals | Calne, Roy (GB) | 1990-12-12 | — | — | EP | disclosed |
| CN-86107826-A | New forskrine derivant | — | 1987-10-14 | — | — | CN | disclosed |
| EP-0227355-A2 | Prodrugs of rapamycin | THE UNIVERSITY OF KANSAS (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4650803-A | WATER-SOLUBLE ANTITUMOR AGENTS | UNIVERSITY OF KANSAS (US) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091424-B2 | Rapamycin derivatives | RICTOR, MTOR, RPTOR | ALDH1A1 3643/4885L3MBTL1 3400/4885MEN1 446/4885 |
| US-20250223297-A1 | NOVEL RAPAMYCIN DERIVATIVES | MTOR, RICTOR, RPTOR | ALDH1A1 4143/4885L3MBTL1 3265/4885MEN1 564/4885 |
| US-20240180894-A1 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | MTOR, RICTOR, RPTOR | ALDH1A1 4604/4885L3MBTL1 1489/4885MEN1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.